MedPath

he efficacy of alogliptin to gastrin and glycemic control in patients with type 2 diabetes under treatment with gastric secretion inhibitor and gastroprotective agents

Not Applicable
Conditions
Patients with type 2 diabetes
Registration Number
JPRN-UMIN000011277
Lead Sponsor
ational Hospital Organization National Kochi Hospital,
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

diabetic ketosis severe infection before and after operation patients with severe trauma past history of allergy against alogliptin

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes and %changes in gastrin and HbA1c after 6 months from baseline
Secondary Outcome Measures
NameTimeMethod
Changes and %changes in the following parameters during the observation period Body weight Office blood pressure Serum creatinine HDL TG LD
© Copyright 2025. All Rights Reserved by MedPath